Search alternatives:
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a non » _ non (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a non » _ non (Expand Search)
-
1101
-
1102
-
1103
Decreased HIF levels associated with hyperoxic cell state.
Published 2008“…<p>(A) Normalized densitometry of HIF-1α protein levels (•),HIF-1β protein levels (▴), and HIF-1 DNA-binding activity (⧫) as presented in <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1000176#pgen-1000176-g005" target="_blank">Figure 5B</a> of the Jiang et al. article. …”
-
1104
-
1105
Decrease in the frequency of FGF-2/EGF addition increases cell death in aOBSCs.
Published 2013“…Graphs show the percentage of cells in each group (<b>D</b>, E13.5 OBSCs; <b>H</b>, aOBSCs). The results represent the mean ± SEM from 3–5 passages from 2 different cell cultures per condition. …”
-
1106
Relationship between Differential Hepatic microRNA Expression and Decreased Hepatic Cytochrome P450 3A Activity in Cirrhosis
Published 2013“…The relative expression (2<sup>-ΔΔCt</sup> mean ± SEM) of hepatic CYP3A4 mRNA was significantly higher in cirrhotic livers (21.76 ± 2.65 vs. 5.91 ± 1.29, P=2.04E-07) but their levels did not significantly correlate with hepatic CYP3A activity (r=-0.43, P=0.08).…”
-
1107
-
1108
-
1109
-
1110
-
1111
-
1112
-
1113
-
1114
-
1115
-
1116
Deterioration of the anammox process at decreasing temperatures and long SRTs
Published 2017“…The long SRT leads to an increase of non-active and non-anammox cells in the reactor, thereby decreasing the biomass-specific activity.…”
-
1117
-
1118
Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc
Published 2025“…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
-
1119
-
1120